Biomarkers for the Early Detection and Progression of Alzheimer’s Disease

摘要: The recent failures of potential disease-modifying drugs for Alzheimer’s disease (AD) may reflect the fact that enrolled participants in clinical trials are already too advanced to derive a benefit. Thus, well-validated biomarkers early detection and accurate diagnosis preclinical stages AD will be crucial therapeutic advancement. combinatorial use derived from biological fluids, such as cerebrospinal fluid (CSF), with molecular imaging neuropsychological testing eventually achieve diagnostic sensitivity specificity necessary identify people earliest when drug modification is most likely possible. In this regard, positive amyloid or tau tracer retention on positron emission tomography imaging, low CSF concentrations amyloid-β 1-42 peptide, high total phospho-tau, mesial temporal lobe atrophy magnetic resonance temporoparietal/precuneus hypometabolism hypoperfusion 18F-fluorodeoxyglucose have all emerged progression AD. However, ultimate biomarker panel involve inclusion novel blood more precisely associated confirmed pathophysiologic mechanisms improve its reliability detecting This review highlights advancements moving field towards achieving goal